awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33567889-B6B3C5D4-A0BF-4D6F-9050-346B4659E780
Q33567889-B6B3C5D4-A0BF-4D6F-9050-346B4659E780
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33567889-B6B3C5D4-A0BF-4D6F-9050-346B4659E780
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.
P2860
Q33567889-B6B3C5D4-A0BF-4D6F-9050-346B4659E780
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33567889-B6B3C5D4-A0BF-4D6F-9050-346B4659E780
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3c4a84aba3e5fda649d169dcb259550660e27d5e
P2860
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.